Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).

  • FEAnalytics.com
  • FEInvest.net
  • FETransmission.com
  • Investegate.co.uk
  • Trustnet.hk
  • Trustnetoffshore.com
  • Trustnetmiddleeast.com

For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.

WHAT INFORMATION DO WE COLLECT ABOUT YOU?

We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.

COOKIES

In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.

HOW WE USE INFORMATION

We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.

ACCESS TO YOUR INFORMATION AND CORRECTION

We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.

WHERE WE STORE YOUR PERSONAL DATA

The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.

CHANGES TO OUR PRIVACY POLICY

Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.

OTHER WEBSITES

Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.

CONTACT

If you want more information or have any questions or comments relating to our privacy policy please email publishing@financialexpress.net in the first instance.

 Information  X 
Enter a valid email address
  Print      Mail a friend       More announcements

Monday 13 August, 2007

AIM

Schedule 1 -Omega Diagnostics

AIM
13 August 2007


    ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION IN ACCORDANCE WITH RULE 2 OF THE AIM RULES FOR
                                                COMPANIES ('AIM RULES')

COMPANY NAME:
Omega Diagnostics Group plc


COMPANY REGISTERED OFFICE ADDRESS AND IF DIFFERENT, COMPANY TRADING ADDRESS (INCLUDING POSTCODES) :
Registered Address:

One London Wall, London EC2Y 5AB



Trading Address:

Omega House, Hillfoots Business Village, Alva, Scotland, FK12 5DQ


COUNTRY OF INCORPORATION:
England & Wales


COMPANY WEBSITE ADDRESS CONTAINING ALL INFORMATION REQUIRED BY AIM RULE 26:
www.omegadiagnostics.com


COMPANY BUSINESS (INCLUDING MAIN COUNTRY OF OPERATION) OR, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS
INVESTING STRATEGY).  IF THE ADMISSION IS SOUGHT AS A RESULT OF A REVERSE TAKE-OVER UNDER RULE 14, THIS SHOULD BE
STATED:
Admission is sought as a result of a reverse take-over under Rule 14.  Omega has conditionally agreed to acquire the
entire issued share capital of Genesis Diagnostics Limited and Cambridge Nutritional Sciences Limited (together '
Genesis-CNS').



Omega is an established business in the medical diagnostics industry which produces and sells a wide range of
immunoassay and infectious disease IVD test kits and other products through a distribution network in more than 100
countries worldwide. Omega operates in a niche market, supplying tests for specific infectious diseases and other
clinical conditions. The infectious diseases addressed by Omega's products include Syphilis, Tuberculosis, Dengue
Fever, Chagas Disease and Malaria. All products are designed for use in clinical laboratories and Rapid Tests are
designed for use at the point of care. Omega currently exports over 95 per cent. of its products.



Genesis-CNS is a growing, profitable, cash-generative business serving the clinical diagnostics market.  Genesis-CNS
supplies test kits to hospital laboratories in the UK and overseas, via a network of distributors, in 27 countries.
Genesis-CNS produces 80 different test kits, plus a line of 24 quality control products, mainly in the areas of
autoimmune diseases and food intolerance as well as providing testing services for food intolerance and some diseases.



The Enlarged Group's main country of operation will be the UK although it will have a distribution network of more than
100 countries worldwide.


DETAILS OF SECURITIES TO BE ADMITTED INCLUDING ANY RESTRICTIONS AS TO TRANSFER OF THE SECURITIES (i.e. where known,
number and type of shares, nominal value and issue price to which it seeks admission and the number and type to be held
as treasury shares):
14,875,693 New Ordinary Shares of 4p each including 7,333,333 Placing Shares at the Placing Price of 30p per share


CAPITAL TO BE RAISED ON ADMISSION (IF APPLICABLE) AND ANTICIPATED MARKET CAPITALISATION ON ADMISSION:
Capital to be raised on Admission - £2,200,000

Expected Market Capitalisation on Admission -  £4,462,708


PERCENTAGE OF AIM SECURITIES NOT IN PUBLIC HANDS AT ADMISSION:
68.7%


DETAILS OF ANY OTHER EXCHANGE OR TRADING PLATFORM TO WHICH THE AIM SECURITIES (OR OTHER SECURITIES OF THE COMPANY) ARE
OR WILL BE ADMITTED OR TRADED:
None


FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS (underlining the first name by which each is known or
including any other name by which each is known):
Directors

David Eric Evans (Non-Executive Chairman)

Andrew William Shepherd (Chief Executive Officer)

Kieron Antony Harbinson (Finance Director)

Michael Stephen Gurner (Non-Executive Director)



Proposed Director

Michael Strachan Walker (Non-Executive Director)


FULL NAMES AND HOLDINGS OF SIGNIFICANT SHAREHOLDERS EXPRESSED AS A PERCENTAGE OF THE ISSUED SHARE CAPITAL, BEFORE AND
AFTER ADMISSION (underlining the first name by which each is known or including any other name by which each is known):

                                        Holding of Existing Ordinary   Holding of New Ordinary Shares of
                                        Shares of 1p each before       4p each after Admission
                                        Admission (as at 3 August
                                        2007)
Michael Strachan Walker*                0%                             29.99%
Kaupthing Singer & Friedlander Group    0%                             13.96%
Brewin Dolphin Securities               0%                             12.10%
Williams de Broe                        0%                             8.07%
Andrew William Shepherd                 26.05%                         6.06%
New Star Asset Management               0%                             5.60%
Scottish Enterprise                     14.71%                         3.05%
Julie Anne Monks Shepherd               7.15%                          1.48%



* shares held through ECS International Trustees (Gibraltar) Ltd


NAMES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (H) OF THE AIM RULES:
None


(i)                  ANTICIPATED ACCOUNTING REFERENCE DATE

(ii)                DATE TO WHICH THE MAIN FINANCIAL INFORMATION IN THE ADMISSION DOCUMENT HAS BEEN PREPARED

(iii)               DATES BY WHICH IT MUST PUBLISH ITS FIRST THREE REPORTS PURSUANT TO AIM RULES 18 AND 19:
(i) 31 March

(ii) For Omega 31 March 2007, for Genesis and CNS 31 October 2006

(iii) December 31 2007, September 30 2008 and December 31 2008



N.B.  unaudited results for the 8 months to 30 June 2007 for Genesis and CNS to be announced on 31 August 2007


EXPECTED ADMISSION DATE:
First Admission Date - 31 August 2007
Second Admission Date - 3 September 2007


NAME AND ADDRESS OF NOMINATED ADVISER:
Landsbanki Securities (UK) Limited

Beaufort House

St. Botolph Street

London EC3A 7QR


NAME AND ADDRESS OF BROKER:
Landsbanki Securities (UK) Limited

Beaufort House

St. Botolph Street

London EC3A 7QR


OTHER THAN IN THE CASE OF A QUOTED APPLICANT, DETAILS OF WHERE (POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL
BE AVAILABLE FROM, WITH A STATEMENT THAT THIS WILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS
SECURITIES:
Copies of the Admission Document are available from www.omegadiagnostics.com



The Admission Document will contain full details about Omega Diagnostics Group PLC and the Admission of it securities
to AIM.
DATE OF NOTIFICATION:
13 August 2007


NEW/ UPDATE:
NEW




                      This information is provided by RNS
            The company news service from the London Stock Exchange